Learn About Fairbanks Pharmaceuticals

  • (3/12/21) Fairbanks patent issued Read more
  • (2/13/21) A new publication in Endocrinology provides important updates on Fairbanks’s ongoing research. Read more
  • (1/30/21) Fairbanks COO Elissa Brown was approved by NIH as Program Director/Principal Investigator, and Fairbanks’s research continues Read more
  • (12/21/20) A new publication in Trends in Encocrinology and Metabolism adds new evidence and findings to a 2010 article foundational to Fairbanks’s research. Read more
  • (12/18/20) Remembering Alan Schneyer, Fairbanks’s founder, CEO and CSO, who passed away suddenly in November, 2020. Read more
  • Fairbanks presented at the NIH Innovation Conference on October 13, and will present at the Emerging Company Showcase at the Life Sciences Summit in November. Read more
  • The abstract for the paper that Fairbanks CEO Dr Alan Schneyer had been scheduled to present at the canceled ENDO 2000 meeting is now available online. Read more
  • Fairbanks won the prestigious 2018 Boston Innovation Prize “Golden Ticket” in October, 2018. Read more
  • Fairbanks was awarded a Phase II $1.83M SBIR grant in June, 2018, to support its work developing transformative diabetes therapies . Read more
  • Scroll through other news in our blog.
  • Read about the science behind our work.
  • Read a summary of the positive niche assessment of Fairbanks’ potential for developing new therapies for type 1 and type 2 diabetes in NIH-funded profile
  • Sign up to the right to receive email updates with our latest news.
Fairbanks employees in the laboratory in Springfield: From left, Nolan Meyer, Alden Richter, Alexa Lopez, and Alan Schneyer